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Background: Chronic hepatitis C is a major public health issue, but there is a gap in the 
literature regarding the effectiveness and safety of direct-acting antiviral agents in the Brazilian 
population. The main aim of this study was to describe the effectiveness of boceprevir and 
telaprevir in patients treated at public health care institutions in Brazil.
Materials and methods: A prospective longitudinal and multicenter study was conducted 
in five centers in the State of Paraná between September 2014 and June 2016. Data regarding 
effectiveness and safety were collected from medical records of patients treated with boceprevir 
or telaprevir. The effectiveness outcome comprised the rapid virological response (RVR). 
Multivariate analysis was performed to verify the influence of independent variables (ie, age, 
gender, baseline viral load) on RVR achievement.
Results: Data were collected from 117 patients with chronic hepatitis C virus (HCV) genotype 1 
infection. Fifteen patients received treatment with boceprevir and 102 received telaprevir. 
The mean age was 51.6 years, 64.1% were male, 44.4% were infected with HCV subtype 1a, 
62.4% had a high baseline viral load ($800,000 IU/mL) and 33% were cirrhotic. Furthermore, 
79.5% of patients achieved RVR (26.7% in the boceprevir group and 87.3% in the telaprevir 
group). Multivariate analysis demonstrated that the type of protease inhibitor (boceprevir or 
telaprevir) and the baseline viral load had an influence on the RVR rate (odds ratio [OR] =0.011; 
95% confidence interval [CI]: 0.001–0.119; P,0.001/OR =13.004; 95% CI: 1.522–111.115; 
P=0.019, respectively).
Conclusion: In this longitudinal multicenter cohort study conducted from the Brazilian 
perspective, differences were found in the RVR rates, favoring telaprevir over boceprevir for 
genotype 1 HCV-infected patients. In addition, the baseline viral load was associated with RVR 
achievement in both evaluated groups. As RVR is also reported in the literature as a predictor 
of the sustained virological response (SVR), further analyses of RVR as predictor of SVR 
outcomes should be further evaluated in Brazil.
Keywords: hepatitis C, rapid virological response, protease inhibitors, telaprevir, boceprevir, 
multicenter
Introduction
With about 3% of the global population infected with the hepatitis C virus (HCV), 
chronic hepatitis C is currently considered the leading cause of end-stage liver disease 
and liver transplantation worldwide.1,2 Genotype 1 is the most common among 
HCV genotypes, and it is responsible for about 83 million cases globally (46% of 
all hepatitis C events).3–5 Worldwide, about 4 million people are infected with HCV 
annually.6 In Brazil, it is estimated that about 2 million people are chronically infected 
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with HCV, with 16,000 new cases of hepatitis C officially 
reported in 2014. However, only 20,000 infected patients are 
diagnosed in the country annually.7,8
As a major public health issue, the eradication of HCV is 
the main goal of pharmacological treatment and is measured 
by the sustained virological response (SVR), ie, undetectable 
serum HCV RNA 12–24 weeks after the end of treatment.9–11 
The rapid virological response (RVR), defined as undetect-
able serum HCV RNA after 4 weeks of treatment, is an 
important predictor of SVR.12
Boceprevir and telaprevir, which target the viral serine 
protease NS3/4A, were the first direct-acting antiviral agents 
approved by the US Food and Drug Administration (FDA) 
for the treatment of chronic hepatitis C.13 With the advent of 
these first-generation protease inhibitors, SVR rates increased 
by 30% in comparison with the standard double therapy 
with polyethylene glycol-modified (pegylated) interferon 
(PegIFN) and ribavirin.14 Boceprevir and telaprevir were 
approved by the Brazilian Health Surveillance Agency 
(ANVISA) and incorporated in the public health system in 
2012 to be used only by patients monoinfected with HCV 
genotype 1.15 Despite the approval of new direct-acting 
antivirals (ie, simeprevir, sofosbuvir and daclatasvir),16 
boceprevir and telaprevir are still in use. However, an evi-
dent gap exists in the literature about the effectiveness and 
safety of these agents in the Brazilian population. Thus, the 
aim of this study was to describe the effectiveness outcomes 
related to the use of the first-generation protease inhibitors 
in addition to double therapy with PegIFN and ribavirin in 
patients treated at public health care institutions in Brazil.
Materials and methods
study design
We conducted a prospective longitudinal and multicenter 
study in five centers of four cities in the State of Paraná 
(Cascavel, Maringá, Londrina and Curitiba), between 
September 2014 and June 2016. Data regarding effective-
ness (virological response) and safety (adverse events and 
drug discontinuation) were collected from the medical 
records of patients with genotype 1 HCV infection in 
triple therapy with either boceprevir plus PegIFN and 
ribavirin or telaprevir plus PegIFN and ribavirin. This study 
was conducted according to the Declaration of Helsinki and 
the Ethics Committee on Human Research of the Hospital 
de Clínicas – UFPR (Curitiba, Paraná, Brazil) approved the 
study protocol (Number 736.348). All participants provided 
written informed consent. The eligibility criteria followed the 
Brazilian guidelines for treating chronic HCV genotype 1 
patients with first-generation protease inhibitors. Thereby, 
eligible patients comprised patients monoinfected with HCV 
genotype 1, those with advanced liver fibrosis (Meta-analysis 
of Histological Data in Viral Hepatitis [METAVIR]17 F3 
or F4), METAVIR F2 nonresponders to previous treatments, 
those without decompensated cirrhosis or those using triple 
therapy with either boceprevir or telaprevir. Patients on 
double therapy only with PegIFN plus ribavirin, coinfected 
with other viral diseases (ie, HIV, hepatitis B), presenting 
signs of hepatic decompensation, or with any contraindica-
tion to the use of telaprevir or boceprevir were excluded.
Data collection
Information collected included sociodemographic data, 
data regarding previous treatments for chronic hepatitis C 
(treatment-naïve or treatment-experienced patients), comor-
bidities (ie, diabetes, systemic arterial hypertension), fibrosis 
stage according to the METAVIR score,17 HCV genotype 
subtype (1a, 1b or 1 undetermined), laboratory tests (hemo-
globin, neutrophil count, platelet count, alanine aminotrans-
ferase [ALT] level, aspartate aminotransferase [AST] level), 
RNA viral load (for pretreatment and follow-up at weeks 4, 
12, 24 and 48 of treatment and at 24 weeks after the end of 
treatment), and adverse events (all side effects reported on 
the medical records during the treatment period, such as 
pruritus and cutaneous rash, were collected). In addition, data 
regarding treatment discontinuation and the reason leading 
to the withdrawal were also gathered. To avoid the effect of 
potential incompleteness of previous virological response 
data on medical records, treatment-experienced patients were 
not categorized as prior relapsers, prior partial responders 
or prior null responders. The participants were followed 
until 6 months after the end of treatment. A positive RVR 
was defined when the HCV RNA was “undetectable” at the 
fourth week of treatment. Patients missing HCV RNA data 
at this time were excluded from the analysis.
This study focuses on the RVR. Hence, all analyses herein 
presented are regarding this efficacy outcome.
statistical analysis
Statistical analyses were conducted using IBM SPSS Sta-
tistics 24 (IBM Corp, Armonk, NY, USA), and a statistical 
probability less than 0.05 was considered to be indicative 
of significance. Categorical data are described as absolute 
and relative frequencies, and continuous data are shown as 
mean and standard deviation (for variables with a normal 
distribution) and as median and range (for variables with a 
non-normal distribution). For the univariate comparisons, 
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categorical variables were analyzed by the Pearson’s chi-
squared test and the continuous variables by Student’s t-test 
or the Mann–Whitney test according to their normal or non-
normal distribution, respectively. The association between 
the categorical variables and the RVR rates was assessed 
by the Pearson’s chi-squared test, and the Spearman Rank 
Correlation test was used for continuous variables. In order 
to measure the influence of several features related to the 
patient (eg, gender) and the disease (eg, fibrosis stage, HCV 
genotype subtype) on the RVR rate, we performed a binary 
logistic regression analysis.
Results
Data from 117 patients with chronic HCV genotype 1 infec-
tion were collected from the medical records of five centers 
in the State of Paraná. With respect to the baseline data, 
the mean age was 51.6 years (SD =9.5), 64.1% were male, 
44.4% were infected with subtype 1a of the virus, 62.4% had 
high baseline viral load ($800,000 IU/mL) with a median 
baseline viral load of 6.1log
10
 IU/mL and 33% were cirrhotic. 
Fifteen patients received treatment with boceprevir and 102 
with telaprevir, 48.7% were treatment naïve, and 72.6% were 
prescribed PegIFN α-2a for the triple therapy. The charac-
teristics of the participants distributed among the boceprevir 
and telaprevir groups differed significantly only regarding 
the HCV genotype subtype and the RVR rate. Details on the 
baseline data are presented in Table 1.
Regarding the RVR rate, 93 patients (79.5%) achieved 
the virological response in the fourth week of treatment with 
the protease inhibitor, including four patients (26.7%) in the 
boceprevir group and 89 patients (87.3%) in the telaprevir 
group (Table 2).
Concerning the association between the variables gender, 
HCV subtype, previous treatment, PegIFN type, baseline 
polymerase chain reaction (PCR) (dichotomized as high 
or low), fibrosis stage, protease inhibitor (boceprevir or 
telaprevir) and RVR attainment, the Pearson’s chi-squared 
test results revealed that only the protease inhibitor and the 
baseline PCR were associated with RVR achievement (χ2 
P,0.001 and P=0.023, respectively). With respect to the 
continuous variables age, baseline hemoglobin, baseline 
neutrophil count, baseline platelet count, baseline ALT, 
Table 1 Baseline characteristics of the study patients
Variables BOC (n=15) TVR (n=102) P-value Total (N=117)
age, years; mean (sD) 53.4 (8.4) 51.3 (9.7) 0.37 51.6 (9.5)
gender, male; n (%) 12 (80.0) 63 (61.8) 0.17 75 (64.1)
hCV subtype; n (%) 0.03* –
1a 2 (13.3) 50 (49.0) – 52 (44.4)
1b 8 (53.3) 32 (31.4) – 40 (34.2)
1 5 (33.3) 20 (19.6) – 25 (21.4)
Previous treatment, n (%) 0.47 –
Treatment naïve 6 (40.0) 51 (50.0) – 57 (48.7)
Treatment experienced 9 (60.0) 51 (50.0) – 60 (51.3)
PegiFn type (prescribed for the TT), n (%) 0.54 –
alfa-2a 10 (66.7) 75 (73.5) – 85 (72.6)
alfa-2b 5 (33.3) 26 (25.5) – 31 (26.5)
nR 0 (0.0) 1 (1.0) – 1 (0.9)
MeTaViR score, n (%) 0.18 –
F1 1 (6.7) 1 (1.0) – 2 (1.7)
F2 3 (20.0) 8 (7.8) – 11 (9.4)
F3 7 (46.7) 56 (54.9) – 63 (53.8)
F4 4 (26.7) 35 (34.3) – 39 (33.0)
nR 0 (0.0) 2 (2.0) – 2 (1.7)
hCV Rna – –
$800,000 iU/ml, n (%) 8 (53.3) 65 (63.7) 0.38 73 (62.4)
log10 iU/ml; median (range) 5.9 (2.3–6.6) 6.1 (3.7–7.0) 0.24 6.1 (2.3–7.0)
hemoglobin, g/dl; median (range) 16.0 (11.0–17.5) 15.1 (9.2–18.2) 0.21 15.1 (9.2–18.2)
neutrophil count,/mm3; median (range) 2,944 (1,500–5,212) 3,060 (1,239–7,455) 0.90 3,056 (1,239–7,455)
Platelets, ×104/mm3; median (range) 14.5 (7.7–44.8) 16.1 (5.4–34.5) 0.52 16.1 (5.4–44.8)
alT, iU/l; median (range) 71.3 (25.0–279.0) 88.8 (17.3–325.0) 0.48 81.2 (17.3–325.0)
asT, iU/l; median (range) 51.0 (23.0–208.0) 58.5 (16.1–242.0) 0.62 57.8 (16.1–242.0)
Note: *Statistically significant.
Abbreviations: alT, alanine aminotransferase; asT, aspartate aminotransferase; BOC, boceprevir; hCV, hepatitis C virus; MeTaViR, Meta-analysis of histological Data in Viral 
hepatitis; nR, not reported; PegiFn, pegylated interferon; Rna, ribonucleic acid; RVR, rapid virological response; sD, standard deviation; TT, triple therapy; TVR, telaprevir.





baseline AST and baseline viral load on RVR achievement, 
a significant correlation was found only for the baseline 
viral load (Spearman’s rho r
s
=0.203, P=0.030). Multivariate 
analysis demonstrated that only the protease inhibitor and 
baseline viral load had influence on the RVR rate (odds ratio 
[OR] =0.011; 95% confidence interval [CI]: 0.001–0.119; 
P,0.001/OR =13.004; 95% CI: 1.522–111.115; P=0.019, 
respectively). The results of the logistic regression are 
expressed in Table 3.
Discussion
Despite the recent approval of IFN-free regimens, which 
have demonstrated great efficacy in several clinical trials for 
the treatment of chronic hepatitis C, many patients still have 
limited access to these new agents.18–20 Therefore, studies 
addressing less-expensive therapies, which are still in use in 
several countries, are needed.
To our knowledge, this is the first observational study 
evaluating the RVR rate promoted by the first-generation 
protease inhibitors, as well as the first multicenter study 
evaluating the effectiveness of these treatments on chronic 
hepatitis C, conducted in a real-life environment in Brazil. 
Poordad et al21 described RVR as a new milestone in the 
treatment of chronic hepatitis C because it is a strong positive 
predictor of SVR and, along with baseline viral load, may 
contribute to the establishment of individualized treatments. 
Subsequently, the evaluation of RVR in observational and 
interventional studies was reported as a predictive factor of 
chronic hepatitis C treatment response.22,23
The results of our multivariate analysis showed that the 
baseline viral load had an influence on the RVR rate. A retro-
spective study conducted by Jensen et al24 in 2006, aiming to 
identify the predictors of RVR and SVR in HCV genotype 1 
patients, revealed that individuals with a low baseline viral 
load (,600,000 IU/mL) were more likely to achieve RVR 
than those with a higher PCR baseline. In addition, patients 
who achieved RVR were more likely to achieve SVR.24
Our results also indicate that the use of triple therapy 
with telaprevir was associated with a higher RVR rate when 
compared to triple therapy with boceprevir (87% vs 27%, 
respectively). Bailly et al25 (the ANRS CO20-CUPIC study) 
evaluated whether RVR is predictive of SVR in a cohort of 
HCV genotype 1 cirrhotic treatment-experienced patients 
treated with telaprevir or boceprevir and reported that RVR 
achievement was almost twofold higher in telaprevir patients 
than in boceprevir patients (67% vs 36%). In contrast, 
Belperio et al26 evaluated the effectiveness of first-generation 
direct-acting antivirals in a cohort of US Veterans Affairs 
patients and reported no statistical difference in the propor-
tion of noncirrhotic treatment-naïve patients achieving RVR 
(58% of the telaprevir group and 49% of the boceprevir 
group; P=0.200).
Concerning the results of clinical trials, in the ADVANCE 
study,27 68% of treatment-naïve patients attained RVR 
Table 2 RVR and changes in viral load after 4 weeks of treatment
Variables Basal viral load, 
IU/mL; mean (SD)





















Notes: #Equal variances not assumed; *Statistically significant.
Abbreviations: BOC, boceprevir; RVR, rapid virological response; sD, standard deviation; TVR, telaprevir.
Table 3 Logistic regression to identify the influence of features 
related to the patient and the disease on RVR rates
Variable P-value Odds 
ratio
95% CI for 
Exp(B)
Lower Upper
Protease inhibitor ,0.001* 0.011 0.001 0.119
gender 0.134 2.658 0.740 9.541
hCV subtype 0.792 1.110 0.512 2.406
Previous treatment 0.824 1.155 0.325 4.104
PegiFn type 0.252 0.404 0.086 1.905
Baseline viral load (low/high) 0.019* 13.004 1.522 111.115
Fibrosis stage 0.239 0.262 0.028 2.429
Baseline hemoglobin 0.270 1.296 0.818 2.052
Baseline neutrophil count 0.346 1.000 1.000 1.001
Baseline platelet count 0.075 1.000 1.000 1.000
Baseline alT 0.165 0.987 0.968 1.006
Baseline asT 0.088 1.023 0.997 1.051
age 0.556 0.981 0.921 1.045
Baseline hCV Rna 0.120 2.032 0.831 4.970
Notes: *Statistically significant. Exp(B) = odds ratios for the predictors.
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; PegIFN, pegylated 
interferon; alT, alanine aminotransferase; asT, aspartate aminotransferase; Rna, 
ribonucleic acid; RVR, rapid virological response.
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with telaprevir, whereas in the REALIZE study,28 57% 
of treatment-experienced patients achieved RVR. In the 
SPRINT-2 study,29 the RVR rate in previously untreated 
patients was 91% with boceprevir, much higher than the 
results of our observational study. Compared with our obser-
vational real-life study, it seems that clinical trials report 
slightly lower RVR rates for telaprevir, but much higher 
rates for boceprevir. These discrepancies form the basis of 
real-life treatment outcome evaluation-based effectiveness 
studies30 and should be taken into consideration when making 
formulary and reimbursement decisions, especially in public 
health care institutions.
Almeida et al31 evaluated the SVR of triple therapy with 
telaprevir or boceprevir in a Brazilian tertiary public hos-
pital. Their population comprised only 24 patients (12 on 
telaprevir and 12 on boceprevir) with baseline character-
istics similar to our cohort, except for a higher number 
of treatment-experienced and cirrhotic patients (79.0% 
and 54.2%, respectively). Of the 12 patients treated with 
telaprevir, 11 (91.7%) achieved RVR, which is similar to 
our rate of 87.3%. The RVR results in the boceprevir group 
were not reported.31
Evidence regarding the influence of RVR on SVR 
achievement has emerged recently. Pearlman and Ehleben,32 
in a randomized open-label trial held in 2014, demonstrated 
that both baseline viral load and RVR are important predictors 
of SVR. They hypothesized that patients with a low baseline 
viral load and who attain RVR after 4 weeks of treatment with 
PegIFN and ribavirin are more likely to achieve SVR, which 
may render the use of a protease inhibitor unnecessary.32 
However, further analyses are required to demonstrate the 
predictive value of baseline viral load and RVR achievement 
on SVR rates in a cohort of Brazilian patients. The long-term 
safety profile of protease inhibitors is also an important aspect 
to be evaluated in real-life studies, because first-generation 
agents are associated with adverse events (cutaneous rash was 
found to be related to telaprevir treatment and dysgeusia and 
anemia were related to boceprevir treatment).33 Therefore, 
further analysis addressing the adverse events associated 
with these agents should be conducted.
As limitations, our study included an unbalanced pro-
portion of patients regarding the protease inhibitor used. 
However, as a real-life study, these percentages represent 
the actual treatment selection in Brazil. Regardless, with 
these figures, we were able to identify statistical differences 
between the two groups of patients.
Our analysis confirms the predictive value of baseline 
viral load on RVR achievement with first-generation protease 
inhibitors. In contrast to clinical trials, we found differences 
in RVR rates in a real-life prospective Brazilian multicenter 
cohort study in favor of telaprevir compared with boceprevir 
for genotype 1 HCV-infected patients with advanced liver 
fibrosis. Further analyses regarding the SVR should be con-
ducted in this context.
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